First Case of Child Cured of HIV

The case of the first child to be cured of HIV was described before a rapt audience at the 2013 Conference on Retroviruses and Opportunistic Infections in Atlanta, GA, March 3.

Dr. Deborah Persaud of Johns Hopkins Children’s Center, an amfAR grantee, detailed the case of a child in Mississippi born to a mother who tested HIV-positive during labor. Because this was the first point of contact between the mother and medical care, the doctors knew she had not taken antiretroviral therapy during pregnancy, an intervention that vastly reduces the chances of mother-to-child transmission of the virus.

With this in mind, the pediatrician in charge of the case, Dr. Hannah Gay, decided to administer a treatment dose, rather than the usual prevention dose, of antiretroviral therapy to the infant just 31 hours after birth, to increase the chances that HIV infection could be prevented. She figured that if the infection occurred despite this therapy, at least the infant would be starting on therapy soon after birth. Infants are normally started on a treatment dose of antiretroviral therapy at six weeks or more, so there would be few other infants who had started antiretroviral treatment so soon after birth.

Tests confirm HIV diagnosis

At roughly the same time that treatment was initiated, two tests were conducted to determine whether the infant was infected. Both tests confirmed the infant was HIV-negative.

Three Types of HIV Cure

WHAT DO THEY MEAN, AND WHERE DO WE GO FROM HERE?

By Rowena Johnston, Ph.D.

On March 3, we heard the news that a child appeared to have been cured of HIV. Hard on the heels of that report came the news that 14 individuals in France had been functionally cured of HIV. So what do these cases mean? How are they similar, and how do they differ? And importantly for HIV research, where do we go from here?

Much depends on how a cure is defined. Researchers are used to thinking of a cure in two different ways. One type, a sterilizing cure, requires that HIV be eradicated from the body of the infected person. The second, a functional cure, is less stringent in that it requires that the patient is able to stop taking antiretroviral therapy without suffering any adverse consequences of the HIV that remains in their body.

The Berlin patient

A decade ago, almost nobody spoke of curing HIV infection as a realistic goal, yet we find ourselves...
FROM THE CEO

Policy vs. Progress

The practical applications of the Mississippi cure case (see cover story) remain to be seen, but this is nonetheless a major step forward in our efforts to cure HIV and an important proof of principle. As you will read in the pages of this newsletter, AIDS research is moving forward on many fronts. The question is, will this exciting progress be matched on the policy front, or will further progress on AIDS be stymied by the same old culprits: ideology and political expediency?

Even today, the AIDS response is hampered in many significant ways by policy makers who cannot see the forest for the trees. Take syringe exchange. Despite reams of evidence that it’s effective—and cost-effective—at blocking the spread of HIV and other blood-borne diseases without increasing drug use, the use of federal funds to support syringe services programs remains prohibited (see facing page).

Global Advocacy Corps Grants Support Analysis and Advocacy

In 2011, amfAR launched the Global Advocacy Corps, a small grants program that supports original policy analysis, reporting, and advocacy throughout the world. These projects are intended to help make national responses to HIV more effective and to support civil society organizations already engaged in advocacy work.

“We’ve seen the positive impact of our own policy analysis and wanted to support this type of work in other countries,” said Owen Ryan, amfAR’s deputy director of public policy. “Civil society advocates throughout the world are often doing analysis and strategic planning with limited or no support. We wanted to change that.”

The Global Advocacy Corps funds community-based organizations that have established themselves as strong advocates but need support to do policy analysis work. “What’s really the premium here is time,” said Ryan. “Analyzing national policy and budget data in a way that effects real change requires smart people and perseverance. We find over and over how effective advocates are pulled in a million directions. We’re hoping the Global Advocacy Corps will provide the resources that allow civil society groups to identify the most important policy changes in their countries.”

Last year, the program funded grants in Nigeria, Uganda, Zimbabwe, Malawi, and Swaziland with a deliberate focus on Sub-Saharan Africa. This year, the program hopes to expand to Eastern Europe and Asia. Ryan says that ultimately he’d like to be able to point to examples of former Global Advocacy Corps grantees who are continuing this type of work on their own in a few years’ time.

For more information, visit www.amfar.org/publicpolicy.html.

INNOVATIONS

The Newsletter of amfAR, The Foundation for AIDS Research
SPRING 2013

120 Wall Street, 13th Floor
New York, NY 10005-3908
tel: (212) 806-1600
fax: (212) 806-1601

1150 17th Street, NW, Suite 406
Washington, DC 20036-4622
tel: (202) 331-8600
fax: (202) 331-8606

TREAT Asia
Exchange Tower
388 Sukhumvit Road, Suite 2104
Klongtoey, Bangkok 10110
Thailand
tel: (+66) 2 663-7561
fax: (+66) 2 663-7562

www.amfar.org

Newsletter Staff
Shaun Raviv
Editor
Andrew McInnes
Director, Public Information
Jessica Ochalek
Staff Writer
Raoul Norman-Tenazas
Creative Director
Yolande Hunter
Creative Coordinator

amfAR meets the BBB Wise Giving Alliance’s Standards for Charity Accountability

amfAR is a Four Star Charity

amfAR-FUNDED ORGANIZATIONS MAKING “REAL CHANGE”
Injection drug use remains a driving force in the HIV epidemic, accounting for 14 percent of new infections among women and 7–11 percent of new infections among men in the United States in 2010. Needle sharing during injection drug use is also the primary driver of hepatitis C infection in the U.S. An issue brief released by amfAR in January asserts that the ban on federal funding for SSPs impedes domestic efforts to meet the goals of the National HIV/AIDS Strategy and to achieve an “AIDS-Free Generation.”

In 2009, Congress removed a 21-year prohibition on the use of federal funds to support SSPs, only to re-impose the ban two years later. In the brief, amfAR argues that a conclusive body of evidence demonstrates SSPs help prevent infection by reducing the re-use and circulation of injecting equipment without increasing drug use or resulting in other negative consequences. SSPs currently operate in 186 U.S. cities, and have been endorsed by numerous medical and public health organizations, as well as law enforcement officials across the U.S.

Despite this consensus, jurisdictions are still not able to use federal funds to support SSPs. The supplies provided by SSPs to prevent new infections are substantially cheaper than the cost of treating HIV or hepatitis C, and SSPs proved a vital link to drug treatment and health care services. Studies have also shown that SSPs provide a significant public safety benefit to communities by reducing the number of improperly discarded syringes, and lowering the risk of needle-stick injuries to law enforcement.

During the brief lifting of the ban on federal funding, federal dollars were used to support SSPs in California, Connecticut, Delaware, Illinois, Massachusetts, Minnesota, New Jersey, New Mexico, New York, Puerto Rico, Vermont, and Washington. The ability to again use federal funds to support SSPs would undoubtedly be welcomed by jurisdictions in these states and in others that are eager to prevent new HIV infections, preserve public resources, and support public health and safety goals.

Read the full report, Federal Funding for Syringe Services Programs: Saving Money, Promoting Public Safety, and Improving Public Health, at www.amfar.org/publicpolicy.html.
amfAR Awards $2 Million in New Research Grants

amfAR has awarded two new rounds of research grants and fellowships totaling almost $2 million. The awards will support the work of a dozen scientists at leading research institutions in the U.S. and Europe. The majority are for cure-focused studies.

Supporting young researchers

The sixth round of Mathilde Krim Fellowships in Basic Biomedical Research, created to support the work of young HIV/AIDS researchers, was announced in December. The new Krim Fellows—Christine Durand, M.D., of Johns Hopkins University School of Medicine; Lucie Etienne, Ph.D., of the Fred Hutchinson Cancer Research Center in Seattle; Alon Herschhorn, Ph.D., of the Dana-Farber Cancer Institute; and Leopold Kong, Ph.D., of the Scripps Research Institute in La Jolla, CA—will each receive $125,000.

“The research being done by these new Krim Fellows is exciting, innovative, and potentially groundbreaking,” said amfAR vice president and director of research Dr. Rowena Johnston. “Each of the Krim Fellows is doing work that could produce major contributions in four separate areas of HIV/AIDS research: cure research, epidemiological research, vaccine development, and treatment development. Each is at the forefront of the current demands for addressing the pandemic.”

Dr. Christine Durand will address the case of the so-called “Berlin patient”—Timothy Brown, the first person known to have been cured of HIV—to determine which of the several interventions was responsible for curing him of HIV. Dr. Durand plans to investigate each of the three major possibilities separately: chemotherapy targeted against cancer, immune suppressive drugs, and the process of stem cell transplantation. The new information will not only help inform us about the contributions of each of these interventions to curing the patient, but may also reveal which are the most important barriers to overcome in the search for a widely available cure for HIV.

Dr. Durand will work with Dr. Robert Siliciano, who is also at Johns Hopkins and is a longtime amfAR grantee. Additionally, Dr. Siliciano has worked closely with other amfAR-funded scientists on cure research through the Foundation’s ARCHE cure consortium.

“What’s particularly gratifying is that several of our current or former grantees are mentoring these Krim Fellows, reinforcing how important amfAR funding is to several generations of scientists,” Johnston said. “Together, they’re making important discoveries that contribute to our understanding of the virus—and how to overcome it.”

Capitalizing on existing opportunities in cure research

In February, eight new grants totaling more than $1.4 million were awarded to research teams from around the world who are working on a variety of cure-focused studies. This round of grants was supported in part by the Foundation for AIDS and Immune Research (FAIR).

To leverage research resources already in place, two projects will provide additional analysis of ongoing clinical trials. One of these trials is examining a pharmacological approach to curing HIV, while the other is exploring gene therapy. In each case, the investigators—Drs. Lars Ostergaard and Rafick-Pierre Sékaly, respectively—will gather additional data and conduct analyses that will broaden our knowledge in the context of the trials.

“Investing wisely in research sometimes means capitalizing on and strengthening opportunities that already exist,” said Johnston. “This round of funding enables amfAR to widen the net of new research ideas and to deepen our understanding of ongoing research projects.”

Another funded project, led by Dr. Satish Pillai at the University of California, San Francisco, will examine how an unusual genetic mutation—CCR5-delta32—may enhance the curability of HIV. He will measure the amount of virus that persists in patients with or without this mutation. His hypothesis derives from the observation that Timothy Brown, as well as two more patients who may also have been cured, all have this mutation. Several months ago, amfAR funded a research project, led by Dr. Timothy Henrich of Brigham and Women’s Hospital, to characterize more fully the HIV status of the latter two patients.

“Whether our funded researchers are working with real-time clinical trial results or building on concurrent research being conducted by amfAR-funded scientists, one thing is clear: We’re only going to find a cure for HIV if we continue to invest in research,” said amfAR CEO Kevin Robert Frost.

More than 87 percent of amfAR’s research grants are dedicated to cure-specific projects. “We’re only going to end this epidemic through smart investments, and we believe cure research is one of the smartest,” Frost said. “If we can continue to marshal the political and financial will to end AIDS, we believe we will do it in our lifetime.”
HIV-positive people might be cured in different ways.

Not trusting the result, Dr. Gay ordered another test, which also came back undetectable. At this point, Dr. Gay contacted her colleague Dr. Katherine Luzuriaga of the University of Massachusetts Medical School for advice. Dr. Luzuriaga, having just established a pediatric HIV cure collaborative with Dr. Persaud with funding from amfAR, knew she had the right team of scientists poised to delve more deeply into this case.

The pediatric collaborative
An amfAR grant awarded to Drs. Persaud and Luzuriaga in September 2012 allowed them to establish a research collaboratory to explore and document possible pediatric HIV cure cases. The collaboratory includes renowned researchers Drs. Stephen Spector and Doug Richman at the University of California, San Diego; Dr. Frank Maldarelli at the National Cancer Institute; and Dr. Tae-Wook Chun at the National Institute of Allergy and Infectious Diseases.

“amfAR’s support has been instrumental in documenting what we believe is a very important case of a functional HIV cure,” said Dr. Persaud. Drs. Persaud and Luzuriaga have been studying pediatric HIV infection for several years with support from the National Institutes of Health as well as amfAR. This latest amfAR grant allowed them to focus their efforts more directly on curing HIV infection in infants.

“The child’s pediatrician in Mississippi was aware of the work we were doing, and quickly notified our team as soon as this young patient’s case came to her attention,” said Dr. Rowena Johnston, amfAR vice president and director of research. “Because the collaboratory was already in place, the researchers were able to mobilize immediately and perform the tests necessary to determine if this was in fact a case of a child being cured.”

According to Dr. Persaud, comprehensive tests have confirmed beyond doubt that both mother and child were HIV positive when the child was born, and today no signs of HIV infection in the child can be detected by the most sensitive means available (see page 6).

This case points to the tantalizing possibility that different populations of HIV-positive people might be cured in different ways.

Proof of principle
The only other documented case of an HIV cure to date remains that of Timothy Brown, the so-called “Berlin patient” (see page 1). “For pediatrics, this is our Timothy Brown,” Dr. Persaud told The New York Times. “It’s proof of principle that we can cure HIV infection if we can replicate this case.”

This new case points to the tantalizing possibility that different populations of HIV-positive people might be cured in different ways. While Mr. Brown’s case was the outcome of a complex, high-risk, and expensive series of procedures, this new case appears to have been the direct result of a comparatively inexpensive course of antiretroviral therapy.

“Given that this cure appears to have been achieved by antiretroviral therapy alone,” said Dr. Johnston, “it is also imperative that we learn more about a newborn’s immune system, how it differs from an adult’s, and what factors made it possible for the child to be cured.”

“It is imperative that we learn more about a newborn’s immune system, how it differs from an adult’s, and what factors made it possible for the child to be cured.”

The Mississippi case also underscores the importance of identifying HIV-positive pregnant women, expanding access to treatment regimens than can prevent mother-to-child transmission, and immediately putting infants on antiretroviral therapy in the event that they are born HIV positive.

“We are proud to have played a leading role in bringing this first pediatric HIV cure to light,” said amfAR CEO Kevin Robert Frost. “The case is a startling reminder that a cure for HIV could come in ways we never anticipated, and we hope this is the first of many children cured of HIV in the months and years to come.”

Child Cured CONTINUED FROM PAGE 1
Three Types of Cure  CONTINUED FROM PAGE 1

in 2013 with not one, nor even two, but three different types of HIV cure. The first cure—the “Berlin patient,” who we now know as Timothy Brown—has been widely reported. Mr. Brown was living in Germany when he was diagnosed with HIV infection in the mid-1990s. His infection was well controlled by antiretroviral therapy until he was diagnosed with acute myeloid leukemia about 10 years later. To treat the cancer, he received a stem-cell transplant, but his doctors took an extra step, finding a donor with a genetic mutation known as CCR5-delta32. Naturally present in around 1–2 percent of Caucasians, this mutation renders people highly resistant to HIV infection. By transplanting cells from a donor with the mutation, doctors knew there was a good chance of curing Mr. Brown’s leukemia and hoped they might also eradicate—or at the very least bring under control—his HIV infection.

Since his transplant five years ago, standard clinical tests have failed to detect any HIV in Mr. Brown’s body, he hasn’t taken any antiretroviral therapy, and he has certainly not manifested any signs or symptoms suggesting he is progressing to AIDS. Although many scientists are still not willing to go so far as to say HIV has been eradicated from Mr. Brown, it seems increasingly likely that any virus that may be left in his body will not rebound and cause health issues associated with HIV disease. This is as good a cure as exists for any disease.

The Mississippi child
Fast forward to March 2013, when a child in Mississippi was reported to have been cured of HIV (see page 1). Knowing that scientists are skeptical regarding any claims of a cure, Drs. Deborah Persaud and Katherine Luzuriaga had set up a pediatric cure collaborative with funding from amfAR. The collaborative included scientists specializing in all the tests that had been done to confirm the cure in Timothy Brown. These highly sensitive tests collectively suggested that if there was any virus left in this child’s body, it was unlikely to be capable of multiplying and causing disease.

As promising as the recent reports of a cure have been, it is clear there is much work to be done to find a cure that can be applied to the 34 million people living with HIV today.

What does it all mean?
What do these three different types of HIV cure tell us? First, there is as yet no cure that can be applied broadly. Timothy Brown’s cure was a grueling and even life-threatening process that cannot be recommended for patients on a wider scale. Moreover, the stem-cell donor in his case had a rare mutation—finding a tissue match for every HIV patient from among these rare gene carriers would be impossible. Mr. Brown’s case has taught researchers which kinds of tests will be needed to satisfy the rightly skeptical scientific community that a cure has taken place.

The potential to apply the findings from the child cure case is intriguing. Each year around the world more than 330,000 infants are born HIV positive. Although a regimen of antiretroviral therapy during pregnancy, sometimes with the addition of a brief regimen in infants after birth, can prevent around 98 percent of mother-to-child transmission of HIV, efforts to scale up this intervention have so far failed to reach all HIV-positive pregnant women. Even with universal coverage, some infants would still be born with HIV. What remains to be determined—and clinical research studies are currently being planned—is whether an early course of antiretroviral treatment in infants for a circumscribed period of time can eliminate HIV infection after it has occurred.

The French cohort
Only a week or two after the child cure story broke, French researchers reported they were following 14 people who were “functionally” cured of HIV. These adults had been treated with antiretroviral therapy during acute infection, i.e., within the first several weeks after becoming infected. All had taken antiretroviral therapy for an average of three years and then stopped. They have now been off therapy for an average of more than seven years, and yet their CD4 cell counts are in the normal range and their viral loads are almost all below 50 copies per milliliter of blood, which is the goal for patients who are taking therapy. Although more sensitive laboratory tests have readily detected HIV in these patients, they appear to no longer need to take antiretroviral therapy to maintain their health, hence the designation “functionally cured.”

amfAR Interview
Renowned virologist, president of the International AIDS Society, and Nobel Laureate Dr. Françoise Barré-Sinoussi recently spoke to amfAR about her work and current directions in cure research. You can find the interview at www.amfar.org/treatasia.
Stopping HIV Using a Cocktail of Genes Rather than Drugs

By Jeffrey Laurence, M.D.

The headline in The Huffington Post heralded this new amfAR-funded work by stating that, “HIV-resistant cells created by Stanford researchers could protect patients from AIDS.” An ABC News blog further declared: “Genetically modified cells could prevent death from HIV/AIDS, study finds.” And what led to all this promise and excitement? amfAR grantees Dr. Matthew Porteus, working in the Department of Pediatrics at Stanford University, and Dr. Sara Sawyer at the University of Texas, have worked with colleagues to create, in the test tube, genetically modified human T cells resistant to HIV infection.

Porteus, Sawyer, and colleagues took a lead from prior amfAR-funded research into so-called “restriction factors,” or normal cellular genes that have the capacity to limit the growth of HIV. Utilizing a novel and complex gene strategy based on enzymes that can cut into a host’s DNA, they were able to insert such factors—including APOBEC3G and TRIM5α—into a host gene, CCR5, disrupting that gene in the process. CCR5 normally codes for a critical receptor, or door, by which most strains of HIV enter a cell.

They refer to this approach as “Genetic HAART,” as it uses a “cocktail,” not of drugs as we normally associate with highly active antiretroviral therapy (HAART), but of genes. But both approaches involve agents with overlapping or different mechanisms of action against HIV, making resistance much less of a risk.

As Porteus explained in his paper, published online in late January in Molecular Therapy, a journal of the American Society of Gene and Cell Therapy, “this strategy provides multiple parallel blocks to infection.” Indeed it did. The researchers were able to protect cells against HIV strains that used the CCR5 pathway as well as other HIV strains that used an alternate “door” to infection, CXCR4.

“This method would give people a protected reservoir of T cells that would thwart immune system collapse, and the secondary infections that give rise to AIDS,” said Dr. Sawyer in the ABC News blog. This work, though as yet only at the test-tube stage, is an important step toward an eventual practical cure for AIDS. ■

Dr. Laurence is amfAR’s senior scientific consultant.

Dr. Matthew Porteus

Dr. Sara Sawyer

Dr. Johnston is amfAR’s vice president and director of research.

www.amfar.org amfAR, The Foundation for AIDS Research

INNOVATIONS, SPRING 2013 7
Supporting GMT-Led Front-Line Groups in Africa and Latin America

amfAR has announced new rounds of grants aimed at reducing the spread and impact of HIV among gay men, other men who have sex with men (MSM), and transgender individuals—collectively known as “GMT”—in Latin America and Africa. The Foundation in 2012 renamed its MSM Initiative to reflect the diversity of populations being served by the program. The 22 awards, which range from $14,400 to $20,000 each, will go to community-led groups working with GMT across the two regions.

“Since we renamed our MSM Initiative last year to become the GMT Initiative, we’ve helped change the global health conversation about the need to address the HIV/AIDS epidemic among transgender individuals in addition to gay men and other MSM,” said GMT Initiative Director Kent Klindera. “We hope our continued efforts will encourage other donors to recognize the importance of working with GMT to curb the epidemic.”

A primary goal of the GMT Initiative is to strengthen the evaluation process for projects funded through the program. One of the eight projects in Latin America that exemplifies this new emphasis on evaluation will be run by ASPI-DH, a group in El Salvador that will build on an earlier GMT Initiative award to train healthcare workers in public health centers about the needs of GMT. Part of the award will pay for evaluators to pose as health center clients in order to appraise the quality of care.

Another goal of the GMT Initiative is to increase the role of advocacy and systems change in funded projects. In its first year of funding, Rock of Hope, a group based in Swaziland—a small country in southern Africa with the world’s highest HIV prevalence—will seek to create such change by engaging local media practitioners to publicly address GMT- and HIV-related stigma and discrimination. Rock of Hope will also train GMT in Swaziland to engage local healthcare providers and provide recommendations for GMT-specific HIV treatment improvements.

“As the GMT Initiative continues to evolve, we’re focusing on strategies that will better serve GMT in the long run, including systems change and evaluation processes that ensure our awards have lasting impact on local populations,” Klindera said. “We know we’re only going to change the tide of the HIV/AIDS epidemic among GMT if the larger population understands the link between HIV/AIDS and homophobia. So it’s important that the projects we fund have concrete goals and operate in a larger context.”

See the full list of GMT Initiative grantees and their projects at www.amfar.org/gmt.

Ecuadorean Trans Advocacy Group’s Study Gains International Attention

Silueta X is a grassroots organization in Ecuador that was started in 2008 by Diane Rodriguez, a transsexual activist. Ms. Rodriguez ran—unsuccessfully as it turned out—for a congressional seat in the leftist Ruptura 25 party in an election held in February. Had she won, she would have been the first transgender person to hold public office in Ecuador and the first openly transgender lawmaker in South America.

Ms. Rodriguez continues her work as the director of Silueta X, a recipient of a 2012 community award from amfAR’s GMT Initiative. The organization promotes human rights for all groups, focusing on young transvestite, transgender, and transsexual individuals, and provides community education and HIV prevention services. With funding from amfAR, the group conducted a study—the first of its kind—to determine which factors influence the transmission of HIV among transgender people and to measure discrimination against transgender people on the Ecuadorian coast.

The project made waves in Ecuador and the findings were reported in El Telégrafo, a major news outlet, as well as by the Ministry of Health. In addition, Silueta X earned the attention of key people and organizations including the Governor of Guayas, the Mayor of Guayaquil, the Ministries of Health, Education, Justice, Interior, and Economic and Social Inclusion, as well as international groups including UNAIDS and the Pan American Health Organization. Leaders from the National AIDS Program, the Ministry of Health, and the Transition Commission for Gender Equality committed to work together to improve the situation reflected by the report.

The results spurred the government to conduct the first survey of LGBT populations in the country’s history. “In this sense we feel proud as transsexuals to have initiated our investigation and motivated the government to follow in our footsteps,” stated a report from the group. Silueta X’s study has provided a jumping-off point from which the organization hopes that other groups in the region will launch similar campaigns for LGBT rights.

To further Silueta X’s work, the GMT Initiative has awarded the group an advocacy grant. The money will be used to help Silueta X advocate for greater access to health and education for transgender people at the national level.
“If everyone has the right to health, why are many of our friends dying from HCV?” asked Hidangmayum Umesh Sharma, treasurer of the Asian Network of People who Use Drugs. Asia is home to 38 percent of the estimated 130–170 million people worldwide chronically infected with hepatitis C virus (HCV). Mr. Sharma is one of approximately five million people (15 percent of all those living with HIV/AIDS) who are co-infected with HIV and HCV.

HCV is a serious health threat and is particularly dangerous for people who are HIV positive. Around 75 percent of infected individuals develop chronic HCV, which can lead to cirrhosis—a potentially fatal condition that can result in liver failure and is a risk factor for liver cancer. HIV-positive patients who have progressed to AIDS and are co-infected with HCV have a 50 percent greater risk of mortality than HCV-uninfected patients.

Research on the burden of chronic HCV infection, disease severity, and the treatment needs of HIV co-infected patients in Asia is badly needed.

HCV is curable with therapy in 50–90 percent of cases, depending on the virus genotype (strain) and patient characteristics, including ethnicity. Asian patients tend to have higher treatment response rates than Caucasian patients, for example.

However, treatment is costly and not routinely offered in resource-limited settings. “An outreach worker, who is the front-line service provider for HCV and HIV education, earns $100 per month and would need to save all of his income for approximately 180 months just to buy medicine to treat his HCV,” said Mr. Sharma. Research on the burden of chronic HCV infection, disease severity, and the treatment needs of HIV co-infected patients in Asia is badly needed.

In 2013, TREAT Asia is initiating the first regional HCV screening study and treatment demonstration project for HIV-positive patients in Asia. Led by TREAT Asia Director of Research Dr. Nicolas Durier, and with scientific and biostatistics support from the Kirby Institute, Sydney, Australia, this innovative project will study the tolerability and effectiveness of HCV treatment in HIV co-infected patients within HIV clinics in Asia. The ultimate goal is to develop a pilot model of care for HCV treatment in resource-limited settings that can be replicated within the region. In addition, the project could generate data to bolster advocacy efforts aimed at securing commitments from governments and donor organizations to expand HCV treatment programs.

The screening study is being funded by the U.S. National Institutes of Health, and the treatment project will be supported by a donation of 200 courses of HCV treatment from Merck and Co. and preferentially priced HCV blood tests from Abbot Molecular. It will be implemented in Bangkok, Thailand, at the Thai Red Cross AIDS Research Centre; Hanoi, Vietnam, at the National Hospital of Tropical Diseases; Jakarta, Indonesia, at Cipto Mangunkusumo Hospital; and Kuala Lumpur, Malaysia, at the University of Malaya Medical Centre.

“With hepatitis C, we are facing a massive epidemic,” said Dr. Durier. “Most people with this infection live in developing countries, and, while we know very effective therapy exists, only a handful of them can access treatment. Medicines have been prohibitively expensive, technical guidance is lacking, and political commitment and international funding are almost nonexistent. All of this needs to be urgently addressed before we are faced with a new epidemic of liver failure.”
Inspiration Gala Los Angeles

Chelsea Handler hosted the third annual Inspiration Gala Los Angeles on October 11, 2012, at Milk Studios. Sarah Jessica Parker presented the Piaget Award of Inspiration to Kevin Huvane for his generous contributions to the fight against AIDS, and Katy Perry performed a stunning acoustic set of some of her most beloved hits, bringing the entire crowd to their feet. The event raised more than $1.3 million.

Special thanks: M·A·C Viva Glam, Piaget, Wells Fargo, Hugo Boss, Tumi, Thom Browne, Grey Goose Vodka, FIJI water (Photos: Getty Images)

Katy Perry donated an autographed guitar, auctioned off by Kristin Davis.

TWO x TWO for AIDS and Art

The 14th annual TWO x TWO for AIDS and Art benefit dinner and contemporary art auction on October 20, 2012, raised $4.5 million for amfAR and the Dallas Museum of Art. Close to 475 people attended the sold-out black-tie event, hosted by Cindy and Howard Rachofsky at their Richard Meier-designed home, The Rachofsky House. A live auction conducted by Sotheby’s North and South America Chairman Jamie Niven included works by Karl Lagerfeld and Richard Phillips, who was honored at a brunch the following day.

Special thanks: Neiman Marcus, Audi of America, Cartier, Sotheby’s, Moët Hennessy USA, todd. event design, creative services, Waldman Bros./Chubb, Flexjet, US Risk, AT&T, Inc., Design Within Reach, Aston Martin of Dallas, Kiehl’s Since 1851, Karl Lagerfeld by Fossil, Gagosian Gallery, The Joule Hotel, GDT, Unified Fine Arts and US Art, FDLUXE, Texas Graphic Resource Inc., PlainsCapital Bank, Nancy Gonzalez, Hillstone/R+D Kitchen, Kohler, Spook Stream (Photos: Kevin Tachman)
amfAR Chairman Kenneth Cole, amfAR Ambassador Janet Jackson, and supermodel Heidi Klum were honored for their exceptional contributions to the fight against AIDS at the 2013 amfAR New York Gala on February 6. The event raised more than $2.3 million. Opening remarks by Sarah Jessica Parker were accompanied by rousing performances by CeeLo Green, Alan Cumming, and Santigold.

On Friday, October 26, amfAR’s generationCURE held its second fundraising event, Masquerade, at The Box in New York City. Nearly 200 young professionals donned masks in support of generationCURE’s goal of raising $120,000 to fund a new, cure-focused research project. The event raised more than $19,000.

On Thursday, December 6, 2012, amfAR held its inaugural Inspiration Miami Beach Party during Art Basel Miami Beach. Guests at the invitation-only dance party at Soho Beach House included amfAR Chairman Kenneth Cole and Maria Cuomo Cole, Russell Simmons, Dita Von Teese, John Demsey, St. Vincent, and Bobby Flay, among many others. The event featured a silent auction of contemporary works of art, and special guest DJ sets.

On Thursday, December 6, 2013, amfAR held its inaugural Inspiration Miami Beach Party during Art Basel Miami Beach. Guests at the invitation-only dance party at Soho Beach House included amfAR Chairman Kenneth Cole and Maria Cuomo Cole, Russell Simmons, Dita Von Teese, John Demsey, St. Vincent, and Bobby Flay, among many others. The event featured a silent auction of contemporary works of art, and special guest DJ sets.

On Friday, October 26, amfAR’s generationCURE held its second fundraising event, Masquerade, at The Box in New York City. Nearly 200 young professionals donned masks in support of generationCURE’s goal of raising $120,000 to fund a new, cure-focused research project. The event raised more than $19,000.

On Friday, October 26, amfAR’s generationCURE held its second fundraising event, Masquerade, at The Box in New York City. Nearly 200 young professionals donned masks in support of generationCURE’s goal of raising $120,000 to fund a new, cure-focused research project. The event raised more than $19,000.

On Friday, October 26, amfAR’s generationCURE held its second fundraising event, Masquerade, at The Box in New York City. Nearly 200 young professionals donned masks in support of generationCURE’s goal of raising $120,000 to fund a new, cure-focused research project. The event raised more than $19,000.

On Friday, October 26, amfAR’s generationCURE held its second fundraising event, Masquerade, at The Box in New York City. Nearly 200 young professionals donned masks in support of generationCURE’s goal of raising $120,000 to fund a new, cure-focused research project. The event raised more than $19,000.

On Friday, October 26, amfAR’s generationCURE held its second fundraising event, Masquerade, at The Box in New York City. Nearly 200 young professionals donned masks in support of generationCURE’s goal of raising $120,000 to fund a new, cure-focused research project. The event raised more than $19,000.

On Friday, October 26, amfAR’s generationCURE held its second fundraising event, Masquerade, at The Box in New York City. Nearly 200 young professionals donned masks in support of generationCURE’s goal of raising $120,000 to fund a new, cure-focused research project. The event raised more than $19,000.

On Friday, October 26, amfAR’s generationCURE held its second fundraising event, Masquerade, at The Box in New York City. Nearly 200 young professionals donned masks in support of generationCURE’s goal of raising $120,000 to fund a new, cure-focused research project. The event raised more than $19,000.

On Friday, October 26, amfAR’s generationCURE held its second fundraising event, Masquerade, at The Box in New York City. Nearly 200 young professionals donned masks in support of generationCURE’s goal of raising $120,000 to fund a new, cure-focused research project. The event raised more than $19,000.

On Friday, October 26, amfAR’s generationCURE held its second fundraising event, Masquerade, at The Box in New York City. Nearly 200 young professionals donned masks in support of generationCURE’s goal of raising $120,000 to fund a new, cure-focused research project. The event raised more than $19,000.

On Friday, October 26, amfAR’s generationCURE held its second fundraising event, Masquerade, at The Box in New York City. Nearly 200 young professionals donned masks in support of generationCURE’s goal of raising $120,000 to fund a new, cure-focused research project. The event raised more than $19,000.

On Friday, October 26, amfAR’s generationCURE held its second fundraising event, Masquerade, at The Box in New York City. Nearly 200 young professionals donned masks in support of generationCURE’s goal of raising $120,000 to fund a new, cure-focused research project. The event raised more than $19,000.

On Friday, October 26, amfAR’s generationCURE held its second fundraising event, Masquerade, at The Box in New York City. Nearly 200 young professionals donned masks in support of generationCURE’s goal of raising $120,000 to fund a new, cure-focused research project. The event raised more than $19,000.
amfAR's collaborative approach to HIV/AIDS research has brought us closer to a cure than ever before—and we need you to be a part of the next crucial discovery. Friends of amfAR is a special group of individuals who provide constant support with monthly pledges. These contributions enable us to fund innovative research into new treatments, prevention methods, and eventually a cure for HIV/AIDS.

Even small regular donations add up. Please join today at the level that's right for you!

Visit www.amfar.org for details.